Opaganib

RedHill Biopharma selected to present opaganib's potential at JPEO-CBRND's 'Host Directed Therapeutics Industry Day' on October 29-30, 2024, in Alexandria, VA, based on its demonstrated capability in prophylaxis, post-exposure prophylaxis, and treatment of exposure to viruses, bacteria, and toxins.

RedHill Biopharma collaborates with Duke University to test opaganib as a potential treatment for phosgene inhalation injury, aiming for FDA approval under the Animal Rule pathway.

BARDA selected opaganib for joint development & funding as a medical countermeasure to treat Ebola virus disease. Opaganib showed a statistically significant increase in survival in an in vivo EBOV model, advancing on the FDA Animal Rule pathway. The 10th anniversary of the West Africa Ebola epidemic highlights the urgent need for effective therapies, with EBOV proving fatal in around half of all cases. Opaganib, a novel host-directed drug, has shown mutation-resistant antiviral and anti-inflammatory activity, representing an alternative therapeutic strategy for biodefense and global health preparedness.

New U.S. patent issued for a novel coronavirus pneumonia biomarker (≤60% FiO₂) prognostic for opaganib's potential efficacy in treating COVID-19. Post-hoc data from opaganib's Phase 2/3 study showed better outcomes in patients with ≤60% FiO₂ levels, including reduced need for supplemental oxygen, intubation/mechanical ventilation, and mortality.